Surgalign Holdings, Inc. (SRGA)

Market Cap	22.07M
Revenue (ttm)	83.24M
Net Income (ttm)	-60.86M
Shares Out	12.76M
EPS (ttm)	-13.12
PE Ratio	n/a
Forward PE	526.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,252
Open	1.64
Previous Close	1.66
Day's Range	1.61 - 1.80
52-Week Range	1.34 - 9.30
Beta	1.78
Analysts	Buy
Price Target	4.34 (+148.0%)
Earnings Date	May 9, 2023

About SRGA

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical p...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 231
• Stock Exchange: NASDAQ
• Ticker Symbol: SRGA

Financial Performance

In 2021, SRGA's revenue was $90.50 million, a decrease of -11.06% compared to the previous year's $101.75 million. Losses were -$84.65 million, 150.6% more than in 2020.

Analyst Forecast

According to 8 analysts, the average rating for SRGA stock is "Buy." The 12-month stock price forecast is $4.34, which is an increase of 148.00% from the latest price.

Price Target

$4.34

(148.00% upside)

Analyst Consensus: Buy